Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study

Published:2019-07 Issue:7 Volume:20 Page:998-1010
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Tilly Hervé,Morschhauser Franck,Bartlett Nancy L,Mehta Amitkumar,Salles Gilles,Haioun Corinne,Munoz Javier,Chen Andy I,Kolibaba Kathryn,Lu Dan,Yan Mark,Penuel Elicia,Hirata Jamie,Lee Calvin,Sharman Jeff P

Publisher

Elsevier BV

Subject

Oncology

Reference19 articles.

1. Long-term outcome of patients in the LNH-98·5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte;Coiffier;Blood,2010

2. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Tilly;Ann Oncol,2015

3. Succeeding in breaking the R-CHOP ceiling in DLBCL: learning from negative trials;Goy;J Clin Oncol,2017

4. Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research;Nowakowski;J Natl Cancer Inst,2016

5. Strategies and challenges for the next generation of antibody–drug conjugates;Beck;Nat Rev Drug Discov,2017

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2024-06-25

2. Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas;Cancers;2024-06-17

3. Disseminated tuberculosis after Polatuzumab‐Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma;Clinical Case Reports;2024-05

4. Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings;Advanced Drug Delivery Reviews;2024-04

5. Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL;Cancer Treatment Reviews;2024-03